Search results for "Immunization"

showing 10 items of 313 documents

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or…

2005

Hepatitis B virus (HBV) core particles carrying the amino-terminal 120 amino acids (aa) of the nucleocapsid (N) protein of the hantaviruses Dobrava, Hantaan or Puumala have been demonstrated to be highly immunogenic in mice when complexed with adjuvants. Here we demonstrate that even without adjuvant, these chimeric particles induced high-titered, and strongly cross-reactive N-specific antibody responses in BALB/c and C57BL/6 mice. The induced N-specific antibodies represented all IgG subclasses. Pre-existing core-specific antibodies did not abrogate the induction of an N-specific immune response by a hantavirus N insert presented on core particles. Therefore, chimeric core particles should…

Orthohantavirusmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySaccharomyces cerevisiaeCross Reactionsmedicine.disease_causeAntibodies ViralVirusMiceOrthohepadnavirusAdjuvants ImmunologicmedicineEscherichia coliAnimalsImmunization ScheduleHantavirusHepatitis B virusMice Inbred BALB CVaccines SyntheticGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesNucleocapsid Proteinsbiology.organism_classificationVirologyHepatitis B Core AntigensMice Inbred C57BLInfectious DiseasesHepadnaviridaeImmunoglobulin Gbiology.proteinMolecular MedicineFemaleAntibodyCarrier ProteinsAdjuvantPlasmidsVaccine
researchProduct

Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants.

2019

Background Data addressing short- and long-term respiratory morbidity in moderate-late preterm infants are limited. We aim to determine the incidence of recurrent wheezing and associated risk and protective factors in these infants during the first 3 years of life. Methods Prospective, multicenter birth cohort study of infants born at 32+0 to 35+0 weeks' gestation and followed for 3 years to assess the incidence of physician-diagnosed recurrent wheezing. Allergen sensitization and pulmonary function were also studied. We used multivariate mixed-effects models to identify risk factors associated with recurrent wheezing. Results A total of 977 preterm infants were enrolled. Rates of recurrent…

PalivizumabMalePediatricsmedicine.medical_specialtymedicine.medical_treatmentImmunologyPulmonary function testingCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHypersensitivityImmunology and AllergyHumans030212 general & internal medicineAsthmaRespiratory SoundsMechanical ventilationPregnancybusiness.industryIncidence (epidemiology)IncidenceInfant NewbornInfantAtopic dermatitisAllergensmedicine.diseaseAsthmaRespiratory Function Tests030228 respiratory systemChild PreschoolPediatrics Perinatology and Child HealthGestationFemaleImmunizationbusinessInfant Prematuremedicine.drugFollow-Up StudiesPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and ImmunologyREFERENCES
researchProduct

IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease

2011

Interleukin (IL)-22 is an effector cytokine, which acts primarily on epithelial cells in the skin, gut, liver and lung. Both pro- and anti-inflammatory properties have been reported for IL-22 depending on the tissue and disease model. In a murine model of allergic airway inflammation, we found that IL-22 is predominantly produced by innate lymphoid cells in the inflamed lungs, rather than TH cells. To determine the impact of IL-22 on airway inflammation, we used allergen-sensitized IL-22-deficient mice and found that they suffer from significantly higher airway hyperreactivity upon airway challenge. IL-22-deficiency led to increased eosinophil infiltration lymphocyte invasion and production…

PathologyPulmonologymedicine.medical_treatmentT-LymphocytesIntracellular Spacelcsh:Medicine10263 Institute of Experimental ImmunologyInterleukin 22Mice0302 clinical medicineLymphocytesPhosphorylationlcsh:ScienceLung0303 health sciencesMultidisciplinaryInterleukin-13T CellsAllergy and HypersensitivityInnate lymphoid cellInterleukinrespiratory systemInnate ImmunityRecombinant Proteins3. Good healthCytokinemedicine.anatomical_structureInterleukin 13CytokinesMedicineTumor necrosis factor alphaBiological Markersmedicine.symptomResearch ArticleSTAT3 Transcription Factormedicine.medical_specialtyImmune CellsImmunologyAntigen-Presenting CellsImmunoglobulinsInflammation610 Medicine & health1100 General Agricultural and Biological SciencesBiology03 medical and health sciences1300 General Biochemistry Genetics and Molecular BiologymedicineRespiratory HypersensitivityAnimalsBiology030304 developmental biologyInflammation1000 MultidisciplinaryTumor Necrosis Factor-alphaInterleukinslcsh:RImmunityEpithelial CellsEosinophilAllergensAsthmaImmunity Innaterespiratory tract diseasesImmune SystemImmunology570 Life sciences; biologylcsh:QImmunizationBiomarkers030215 immunology
researchProduct

Contact hypersensitivity to disodium hexachloroplatinate in mice.

1998

Complex platinum (Pt) compounds are known as occupational respiratory sensitizers whereas their role in skin exposure is unclear. In this study, both skin irritation and induction of contact hypersensitivity by halide Pt salts were characterized in mice. Repeated application of Na2[PtCl6] (5% in acetone) to both ears of naive BALB/c mice induced activation of the draining auricular lymph nodes. Flow cytometric analysis revealed a striking increase in the number of lymph node cells expressing proliferating cell nuclear antigen. In separate experiments, Na2[PtCl6] or acetone were applied only to the right ear of mice on 4-8 consecutive days and the animals were challenged on the left ear 6 da…

Pathologymedicine.medical_specialtyPharmacologyToxicologyDermatitis Contactchemistry.chemical_compoundMiceProliferating Cell Nuclear AntigenmedicineAnimalsHumansRespiratory systemAllergic contact dermatitisSensitizationSodium hexachloroplatinateMice Inbred BALB CChemistryLocal lymph node assayEarGeneral Medicinemedicine.diseasemedicine.anatomical_structureToxicityDermatitis IrritantFemaleImmunizationLymphLymph NodesCisplatinContact dermatitisToxicology letters
researchProduct

Precise reply and clarifications on behalf of Sicilian Public Health Authorities to the case report published by La Rosa and collegues

2016

The intussusception is one of the most frequent causes of occlusive syndrome in infants and in children.1 The mesenteric lymphadenopathy, wich is very rare post rotavirus vaccination, can cause intussusception,2-5 especially in genetically predisposed individuals.6 There is an association between intussusception and some classes of genotype.7-9 Two infants aged 3 months, vaccinated against rotavirus. After about a week, one of the 2 identical infants presented inconsolable crying, vomiting, loose stools mixed with blood, and was diagnosed with bowel obstruction with intussusception. He was operated in urgency. After a few hours, his brother presented vomiting, and was admitted to our Hospit…

Pediatricsmedicine.medical_specialtyImmunologyTwinsCase ReportPublic administrationRotavirus vaccinationSettore MED/42 - Igiene Generale E ApplicataRotavirus Infections03 medical and health sciencesHealth services0302 clinical medicine030225 pediatricsMedicineHumansImmunology and Allergy030212 general & internal medicineImmunization scheduleSicilyintussusceptionPharmacologybusiness.industryImmunization ProgramsPublic healthHealth PolicyRotavirus VaccinesInfantrotavirus vaccinationlanguage.human_languageClinical PracticeImmunization schedule; intussusception; pediatric population; rotavirus vaccination; Immunology and Allergy; Immunology; PharmacologylanguageMass vaccinationbusinessIdentical twinsSicilianpediatric populationPediatric population
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct

Transient suppression of atopy in early childhood is associated with high vaccination coverage.

2003

Objective. To analyze prevalences of allergic sensitization and atopic disease in relation to vaccination coverage. Methods. A German atopy risk-enhanced birth cohort of 1314 neonates who were born in 1990 in 5 German cities was studied. A total of 943 children participated in the follow-up visit at 5 years of age. Atopic symptoms and diagnoses (derived from structured interviews), total serum immunoglobulin E, and specific immunoglobulin E against 9 common allergens (CAP Radio-Allergo-Sorbent Test Fluoro-Enzyme Immunoassay) were evaluated. Children were grouped into dose percentiles according to cumulative doses of any vaccine given up to 5 years of age (<10%, 0–11 doses; 10%–50%, 1…

Pediatricsmedicine.medical_specialtyPercentileDose-Response Relationship ImmunologicImmunoglobulin EDermatitis AtopicAtopyRadioallergosorbent TestHypersensitivityMedicineHumansEarly childhoodSensitizationAsthmaVaccinesbiologybusiness.industryImmunization ProgramsVaccinationInfant NewbornInfantAtopic dermatitisImmunoglobulin Emedicine.diseaseAsthmamedicine.anatomical_structureVaccination coverageChild PreschoolPediatrics Perinatology and Child Healthbiology.proteinbusinessFollow-Up StudiesPediatrics
researchProduct

Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combi…

2006

Abstract Background To evaluate immunogenicity, reactogenicity, and safety of a hexavalent combination vaccine diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) when coadministered with a 7-valent pneumococcal conjugate vaccine (PCV7). Methods Infants received either a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus- H. influenzae type b vaccine concomitantly with PCV7 or DTPa-HBV-IPV/Hib alone infants were vaccinated at 2, 3 and 4 months (primary immunization) and 12–15 months of age (booster dose). Local and systemic reactions and adverse events were monitored following each do…

Pediatricsmedicine.medical_specialtyPopulationBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansHepatitis B VaccinesVaccines CombinededucationWhooping coughBacterial CapsulesHaemophilus Vaccineseducation.field_of_studyReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusDiphtheriaPolysaccharides BacterialPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesImmunologyAntibody FormationMolecular MedicineImmunizationbusinessmedicine.drugVaccine
researchProduct

Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus.

2008

Objectives: Rotavirus (RV) is the most common etiological agent of gastroenteritis in children. The oral vaccine Rix4414 was recently commercialized in Italy for prevention of RV infections. The health outcomes and the economic impact of a national RV immunization program were assessed.

Pediatricsmedicine.medical_specialtybusiness.industryHealth PolicyRotavirusSettore MED/42 - Igiene Generale e ApplicatamedicineImmunization programPharmacology (medical)Health outcomesmedicine.disease_causebusiness
researchProduct

A combination vaccine against measles, mumps, rubella and varicella.

2008

A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…

Pediatricsmedicine.medical_specialtymedicine.vaccineMeaslesRubellaChickenpox VaccineChickenpoxmedicineHumansPharmacology (medical)Vaccines CombinedSeroconversionChildMumpsImmunization ScheduleRubellaPharmacologyAttenuated vaccineMMRV vaccinebusiness.industryVaccinationAntibody titerInfantGeneral Medicinemedicine.diseaseVirologyVaccinationTolerabilityChild PreschoolbusinessMeasles-Mumps-Rubella VaccineMeaslesDrugs of today (Barcelona, Spain : 1998)
researchProduct